Clinical Spectrum and Outcome of Guillain-Barré Syndrome with Plasmapheresis

Context: Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy and has several electrophysiological subtypes and clinical variants. Treatment is mainly supportive and immunotherapy is given to shorten the disease course. Aims: The aim of this study was to define the outcome of GBS with p...

Full description

Saved in:
Bibliographic Details
Main Authors: Safia Bano, Zomer Sardar, Muhammad Ahmar, Sumayyah Liaquat, Bilal Shafiq, Ahsan Numan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-10-01
Series:Indian Journal of Medical Specialities
Subjects:
Online Access:https://journals.lww.com/10.4103/injms.injms_50_22
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849224427306221568
author Safia Bano
Zomer Sardar
Muhammad Ahmar
Sumayyah Liaquat
Bilal Shafiq
Ahsan Numan
author_facet Safia Bano
Zomer Sardar
Muhammad Ahmar
Sumayyah Liaquat
Bilal Shafiq
Ahsan Numan
author_sort Safia Bano
collection DOAJ
description Context: Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy and has several electrophysiological subtypes and clinical variants. Treatment is mainly supportive and immunotherapy is given to shorten the disease course. Aims: The aim of this study was to define the outcome of GBS with plasmapheresis and to determine its clinical spectrum. Materials and Methods: The prospective study was done at Mayo Hospital, Lahore, for 1 year from November 2020 to November 2021. The diagnosis of GBS was made on Brighton criteria for GBS. The outcome of therapy was assessed at 3 and 6 months, using the Medical Research Council Scale and Hughes Functional Grading Scale (HFGS). Results: A total of 50 patients were enrolled in the study. Twenty-seven (54%) were males and 23 (46%) were females. Seventeen (34%) had acute motor axonal neuropathy, 16 (32%) had acute motor and sensory axonal neuropathy, 15 (30%) had acute inflammatory demyelinating polyradiculoneuropathy, and 2 (4%) had Miller-Fisher syndrome. Plasmapheresis was done in all patients. HFGS score was assessed at discharge, at 3 months, and after 6 months of illness onset. The improvement in mean HFGS score was 2.79 ± 0.41 at 3 months and 1.94 ± 0.25 at 6 months of symptoms onset from the mean score of 3.46 ± 0.93 at the time of discharge from the hospital. Conclusion: Excellent outcome was observed after plasmapheresis. Majority of participants were able to walk without support at the 6-month follow-up. Plasmapheresis should be initiated early in the management of GBS where intravenous immunoglobulins are costly.
format Article
id doaj-art-366095c034e445a1849b333f916c1559
institution Kabale University
issn 0976-2884
0976-2892
language English
publishDate 2022-10-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Medical Specialities
spelling doaj-art-366095c034e445a1849b333f916c15592025-08-25T08:38:34ZengWolters Kluwer Medknow PublicationsIndian Journal of Medical Specialities0976-28840976-28922022-10-0113422623010.4103/injms.injms_50_22Clinical Spectrum and Outcome of Guillain-Barré Syndrome with PlasmapheresisSafia BanoZomer SardarMuhammad AhmarSumayyah LiaquatBilal ShafiqAhsan NumanContext: Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy and has several electrophysiological subtypes and clinical variants. Treatment is mainly supportive and immunotherapy is given to shorten the disease course. Aims: The aim of this study was to define the outcome of GBS with plasmapheresis and to determine its clinical spectrum. Materials and Methods: The prospective study was done at Mayo Hospital, Lahore, for 1 year from November 2020 to November 2021. The diagnosis of GBS was made on Brighton criteria for GBS. The outcome of therapy was assessed at 3 and 6 months, using the Medical Research Council Scale and Hughes Functional Grading Scale (HFGS). Results: A total of 50 patients were enrolled in the study. Twenty-seven (54%) were males and 23 (46%) were females. Seventeen (34%) had acute motor axonal neuropathy, 16 (32%) had acute motor and sensory axonal neuropathy, 15 (30%) had acute inflammatory demyelinating polyradiculoneuropathy, and 2 (4%) had Miller-Fisher syndrome. Plasmapheresis was done in all patients. HFGS score was assessed at discharge, at 3 months, and after 6 months of illness onset. The improvement in mean HFGS score was 2.79 ± 0.41 at 3 months and 1.94 ± 0.25 at 6 months of symptoms onset from the mean score of 3.46 ± 0.93 at the time of discharge from the hospital. Conclusion: Excellent outcome was observed after plasmapheresis. Majority of participants were able to walk without support at the 6-month follow-up. Plasmapheresis should be initiated early in the management of GBS where intravenous immunoglobulins are costly.https://journals.lww.com/10.4103/injms.injms_50_22guillain-barré syndromehughes functional grading scaleintravenous immunoglobulinsoutcomeplasmapheresis
spellingShingle Safia Bano
Zomer Sardar
Muhammad Ahmar
Sumayyah Liaquat
Bilal Shafiq
Ahsan Numan
Clinical Spectrum and Outcome of Guillain-Barré Syndrome with Plasmapheresis
Indian Journal of Medical Specialities
guillain-barré syndrome
hughes functional grading scale
intravenous immunoglobulins
outcome
plasmapheresis
title Clinical Spectrum and Outcome of Guillain-Barré Syndrome with Plasmapheresis
title_full Clinical Spectrum and Outcome of Guillain-Barré Syndrome with Plasmapheresis
title_fullStr Clinical Spectrum and Outcome of Guillain-Barré Syndrome with Plasmapheresis
title_full_unstemmed Clinical Spectrum and Outcome of Guillain-Barré Syndrome with Plasmapheresis
title_short Clinical Spectrum and Outcome of Guillain-Barré Syndrome with Plasmapheresis
title_sort clinical spectrum and outcome of guillain barre syndrome with plasmapheresis
topic guillain-barré syndrome
hughes functional grading scale
intravenous immunoglobulins
outcome
plasmapheresis
url https://journals.lww.com/10.4103/injms.injms_50_22
work_keys_str_mv AT safiabano clinicalspectrumandoutcomeofguillainbarresyndromewithplasmapheresis
AT zomersardar clinicalspectrumandoutcomeofguillainbarresyndromewithplasmapheresis
AT muhammadahmar clinicalspectrumandoutcomeofguillainbarresyndromewithplasmapheresis
AT sumayyahliaquat clinicalspectrumandoutcomeofguillainbarresyndromewithplasmapheresis
AT bilalshafiq clinicalspectrumandoutcomeofguillainbarresyndromewithplasmapheresis
AT ahsannuman clinicalspectrumandoutcomeofguillainbarresyndromewithplasmapheresis